To unravel the potential biological explanations on the sex‐base heterogeneity in treatment response, we also surveyed the neoantigen burden and expression level of several tumor immune microenvironmental related markers tested by multiplex immunofluorescence (mIF) assays in pretreatment tumor tissue samples, including PD‐L1, CD8, CD4, FOXP3, CD68, and their biological combinations, between male and female patients. This evidence concerns the gene CD4 and neoplasm.